AP NEWS

Investigation Report on China’s Loratadine Market, 2018-2022 - ResearchAndMarkets.com

January 2, 2019

DUBLIN--(BUSINESS WIRE)--Jan 2, 2019--The “Investigation Report on China’s Loratadine Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The incidences of common skin redness, itching and rashes and respiratory allergies are rising as China’s economy develops, the living environment and dietary structure change, and environmental pollution intensifies, which drives the growth of the antihistamine market.

Developed by Schering-Plough which has been acquired by Bayer, Loratadine (trade name: Clarityne) was first launched in Belgium in 1988 and then sold in several European countries. In Apr. 1993, it was approved by the FDA to be marketed in the U.S. In Sept. 2002, it was launched in Japan. In November of the same year, the FDA approved Clarityne as a non-prescription drug.

According to research, in Jun. 1993, imported Loratadine tablets were approved to be sold in China under the trade name Clarityne. In 2005, the CFDA approved Clarityne as a non-prescription drug for its excellent effect and long-tested safety. Many Chinese companies have launched generic Loratadine products in the dosage forms of oral tablets, capsules, granules, syrup and compound preparation.

The market competition is fierce but the brand-name drug still has great advantages. In 2017, Shanghai Schering-Plough Pharmaceutical Co., Ltd. and Schering-Plough occupied about 65% market share by sales value. But the market share of the brand-name drug showed a downward trend.

Loratadine has secured a place on the market by advantage of long-lasting and quick-acting effect and rare adverse reactions. However, with the increasing number of Loratadine manufacturers and intensifying competition on the market, the average price of Loratadine is declining.

It is expected that as the incidences of allergic diseases continue to increase, China’s Loratadine market will still has some growth potential in the next few years.

Companies Profiled

Beijing SL Pharmaceutical Co. Ltd. Jiangsu Hanchen Pharmaceutical Co. Ltd. Schering-Plough Shanghai Schering-Plough Pharmaceutical Co. Ltd. Venturepharm Pharmaceutical (Hainan) Co. Ltd.

Topics Covered

Situation of allergic diseases in China Status of China’s Loratadine market Competition on China’s Loratadine market Prices of Loratadine in China Major factors influencing development of China’s Loratadine market Prospect of China’s Loratadine market from 2018 to 2022

List of Chapters

1 Relevant Concepts of Loratadine

2 Sales of Loratadine in China, 2013-2017

3 Analysis of Major Loratadine Manufacturers in China, 2013-2017

4 Prices of Loratadine in China, 2017-2018

5 Prospect of China’s Loratadine Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/dxb95q/investigation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005260/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/02/2019 06:53 AM/DISC: 01/02/2019 06:53 AM

http://www.businesswire.com/news/home/20190102005260/en

AP RADIO
Update hourly